Adjusting Antibiotic Treatment Using Presepsin Levels in Patients Undergoing Thoracic Aorta Surgery

What this Trial Is About

Researchers are exploring the use of presepsin, a biomarker valuable for diagnosing sepsis and predicting postoperative inflammatory complications, in patients undergoing thoracic aorta surgery. This study aims to improve antibacterial therapy decisions based on presepsin levels to reduce infection-related complications after surgery. Previous findings suggest presepsin levels can indicate risks for adverse outcomes during the postoperative period in cardiac surgery patients. Participants undergo reconstructive thoracic aorta surgery and are monitored for presepsin levels at the end of surgery and six hours afterward. Those meeting specific criteriapresepsin above 519.5 pgml at surgery end and no increase after six hoursmay switch to an antibacterial treatment with ampicillinsulbactam 3 g every six hours for at least 72 hours. Patients with presepsin below this threshold continue on cefazolin 2 g every six hours for a minimum of 72 hours postoperatively. During the study, participants are observed for up to 10 days to track infectious complication rates, mortality, length of hospital and ICU stays, multiorgan failure, and the total number of patients with complicated courses. The study evaluates how adjusting antibacterial therapy based on presepsin dynamics may impact these outcomes, with close monitoring to assess safety and effectiveness throughout the postoperative period.

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients